Early invikafusp alfa trial records no disease progression in 16 of 27 at optimal biological doses

In the phase 1/2 START-001 trial, 16 of 27 participants at optimal biological doses had no disease progression, NIH reports; four had targeted tumors shrink by more than 30%. Most participants had tumors resistant to immune checkpoint blockade. NIH called optimal-dose treatment well tolerated, while the Nature Medicine abstract reports two reversible dose-limiting toxicities. The findings are early and do not establish lasting benefit.